tldrdailynews.com logo

Acelyrin's IPO Success: Valued at $2.1 Billion with 28% Stock Jump.

1 min read
Source: Reuters
Acelyrin's IPO Success: Valued at $2.1 Billion with 28% Stock Jump.
Photo: Reuters
TL;DR

Biopharma company Acelyrin Inc. had a strong market debut on Nasdaq, with shares rising 28% and giving the company a market capitalization of $2.1 billion. The Los Angeles-based company raised $540 million by selling 30 million shares in an upsized offering. Acelyrin joins a spate of new listings recently that have fueled hopes of a recovery in IPO markets, including Johnson & Johnson's consumer health business Kenvue Inc.

Topics:businessfinance#acelyrin#biopharma#finance#ipo#johnson-and-johnson#market-debut
Share this article
  1. Biopharma firm Acelyrin valued at $2.1 billion in strong market debut  Reuters
  2. Acelyrin sets out massive $540M upsized IPO  FierceBiotech
  3. Acelyrin Raises $540M In IPO, Stock Gains Over 20% In Trading Debut  Yahoo Finance
  4. Acelyrin Shares Jump 28% in Debut After Upsized IPO  MarketWatch
  5. Acelyrin makes a splash with IPO, biopharma expects to raise $540M  MM+M Online

Want the full story? Read the original reporting

Read on Reuters